Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Long-Term Debt Repayments (2016 - 2019)

Historic Long-Term Debt Repayments for Fate Therapeutics (FATE) over the last 6 years, with Q4 2019 value amounting to $14.0 million.

  • Fate Therapeutics' Long-Term Debt Repayments changed N/A to $14.0 million in Q4 2019 from the same period last year, while for Dec 2019 it was $22.8 million, marking a year-over-year change of. This contributed to the annual value of $15.0 million for FY2019, which is N/A changed from last year.
  • According to the latest figures from Q4 2019, Fate Therapeutics' Long-Term Debt Repayments is $14.0 million.
  • Fate Therapeutics' Long-Term Debt Repayments' 5-year high stood at $14.0 million during Q4 2019, with a 5-year trough of -$389000.0 in Q3 2015.
  • Over the past 4 years, Fate Therapeutics' median Long-Term Debt Repayments value was $2.0 million (recorded in 2016), while the average stood at $3.6 million.
  • As far as peak fluctuations go, Fate Therapeutics' Long-Term Debt Repayments soared by 59820.05% in 2016, and later skyrocketed by 736.79% in 2017.
  • Quarter analysis of 4 years shows Fate Therapeutics' Long-Term Debt Repayments stood at -$389000.0 in 2015, then soared by 607.71% to $2.0 million in 2016, then surged by 239.7% to $6.7 million in 2017, then soared by 108.67% to $14.0 million in 2019.
  • Its Long-Term Debt Repayments was $14.0 million in Q4 2019, compared to $6.7 million in Q3 2017 and $2.0 million in Q2 2017.